Novartis New Organizational Model

Novartis executive team focused on high performance 3 changes Integrated IM 1 business, with US and International at ECN 2 Executive Committee of Novartis 2 Vasant Narasimhan Chief Executive Officer Integrated Strategy, Growth & Portfolio Jay Bradner President, NIBR 3 Shreeram Aradhye¹ President, Global Drug Development & Chief Medical Officer External² Chief Strategy & Growth Officer Marie-France Tschudin President, IM International & CCO Single Operations unit and integrated global G&A functions Steffen Lang President, Operations Harry Kirsch Chief Financial Officer Karen Hale Chief Legal Officer 1 Executive Committee Members Victor Bulto³ President, IM US Rob Kowalski Chief People & Organiz. Officer Klaus Moosmayer Chief Ethics, Risk and Compliance Officer Kees Roks4 Chief Audit Officer Lutz Hegemann President, Global Health 1. Effective May 16 2. L. Hegemann to act as ad-interim for Chief Strategy & Growth Officer 3. ECN member effective May 1, 2022 4. Effective May 1, 2022 11 NOVARTIS NEW ORGANIZATIONAL MODEL | APRIL 04, 2022 | NOVARTIS INVESTOR PRESENTATION Michael Willi Chief Communications Officer Richard Saynor Chief Executive Officer Sandoz NOVARTIS | Reimagining Medicine

View entire presentation